An observational study in Congestive Heart Failure and Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.
Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2026, is one of 21 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 69th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 3 · Phase 4 1
First in 1997; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 36 across the 48 interventional studies, 63 across the 18 observational. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
9 of the studies in Heart Failure by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06874556Mayo ClinicA Study of Paramedic HF Management | 2026-12 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
| NCT06660732Mayo ClinicRilonacept in Subjects With Cardiac Sarcoidosis | 2027-03 |
| NCT05592847Mayo ClinicA Study of the Effect of a Nurse Navigator Program on High Risk Patients | 2027-04 |
| NCT07083011Mayo ClinicA Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 69 studies in Heart Failure by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to expand subject matter expertise and sustained capacity for equity-oriented care within the Advanced Care Ecosystem (ACE) by engaging patients, caregivers, community health workers (CHW), and care-team stakeholders in development work focused on adults living with congestive heart failure (CHF) and adverse social determinants of health (SDoH).
The study population will include adults with congestive heart failure (CHF) who receive primary care at Mayo Clinic in Rochester and have evidence of adverse social determinants of health, elevated health care utilization, or other medical or social complexity relevant to CHF self-care and transitions-of-care support. Eligible patients may nominate adult caregivers or family members to participate when their perspective is relevant to the patient's CHF care experience. The study will also include adult Community Health Workers, chronic disease nurse care coordinators, education specialists, clinicians, and other clinical or operational stakeholders with roles relevant to CHF care, transitions of care, social needs, patient education, or CHW workflows.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients living with congestive heart failure (CHF):
Caregivers:
Community health worker and care-team stakeholders:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults living with CHF receiving primary care at Mayo Clinic Rochester with adverse SDoH, elevated utilization, or related medical/social complexity
Other: Interviews and group discussion for patients and caregivers
Caregivers or family members of eligible CHF patients nominated by the patient
Other: Interviews and group discussion for patients and caregivers
Community health workers, chronic disease RN care coordinators, education specialists, clinicians, and operational leaders
Other: Interviews and group discussion for community health worker and care-team stakeholders
Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes, conducted in person, by telephone, or by Mayo-approved video platform. Interview and discussion guides will include discussion of barriers, facilitators, preferences, priorities, and care gaps related to congestive heart failure self-care, access, transitions of care, community health worker support, caregiver support, social needs, health literacy, language access, trust, and culturally responsive care.
Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes. Interview and discussion guides will focus on development of a community health worker competency-based training module and development of workflows for community health workers to support congestive heart failure patients' self-management and care transitions. Participants will provide feedback on implementation barriers and facilitators, including training burden, role clarity, sustainability, cultural responsiveness, and integration with clinical care teams.
Identification of prioritized barriers to self-care
Total number of prioritized barriers to equitable congestive heart failure self-care and transitions-of-care support identified through participant interviews and group discussions.
Time frame: Through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 24 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.